Actualités thérapeutiques dans les néoplasies myéloprolifératives non LMC

The treatment of polycythemia vera and essential thrombocythemia aims to limit the risk of thrombo-hemorrhagic complications, to preserve the quality of life and to prevent the risk of long-term hematologic transformation. In primary myelofibrosis, the patient's general condition and the severity of the disease should be assessed to adopt the best therapeutic strategy including new therapies and bone marrow transplantation. In all cases, the presentation in a hematological mutidisciplinary board is strongly recommended and place of molecular biology is growing.